Although its deal with Almirall S.A. (Madrid:ALM) doesn't give AstraZeneca plc (LSE:AZN; NYSE:AZN) any clinical assets with mechanisms of action it doesn't already have, the pharma will accelerate its time to market with a LAMA/LABA combination, and add molecules that can be used to develop combination therapies on either a metered-dose inhaler (MDI) or dry powder inhaler (DPI) platform. ICS = inhaled corticosteroid; LABA = long-acting adrenergic receptor beta 2 (ADRB2) agonist; LAMA = long-acting muscarinic receptor